GGrantIndex
← Search

CORE--TRANSGENIC MOUSE/EMBRYONIC STEM CELL FACILITY

$289,716P30FY2000CANIH

University Of Chicago, Chicago IL

Investigators

Linked publications, trials & patents

Paper 39661064Paper 39579248Paper 39438113Paper 39374047Paper 39270007Paper 39141403Paper 39114540Paper 39108474Paper 39071306Paper 39069988Paper 38883758Paper 38881356Paper 38849889Paper 38810242Paper 38771643Paper 38752924Paper 38735044Paper 38716867Paper 38691450Paper 38632339Paper 38561491Paper 38548994Paper 38536082Paper 38533736Paper 38496521Paper 38427437Paper 38421866Paper 38381713Paper 38294692Paper 38294689Paper 38293065Paper 38219706Paper 38213818Paper 38190286Paper 38186960Paper 38175791Paper 38155245Trial NCT02573363Trial NCT02573220Trial NCT02542202Trial NCT02540876Trial NCT02485535Trial NCT02420210Trial NCT02399371Trial NCT02389517Trial NCT02366819Trial NCT02333188Trial NCT02333162Trial NCT02275533Trial NCT02258659Trial NCT02213913Trial NCT02199665Trial NCT02122172Trial NCT02046421Trial NCT02012296Trial NCT01949740Trial NCT01861301Trial NCT01696955Trial NCT01576172Trial NCT01307618Trial NCT01281176Trial NCT01278615Trial NCT01267266Trial NCT01256385Trial NCT01208051Trial NCT01174264Trial NCT01122888Trial NCT01076543Trial NCT01064622Trial NCT00859937Trial NCT00720174Trial NCT00504153Trial NCT00436579Trial NCT00387335Trial NCT00381641Trial NCT00376688Trial NCT00369551Trial NCT00351975Trial NCT00303862Trial NCT00290472Trial NCT00265798Trial NCT00126542Trial NCT00095784Trial NCT00091026Trial NCT00087373Trial NCT00062075Trial NCT00058019Trial NCT00055913Trial NCT00039416Trial NCT00027703Trial NCT00023946Patent 7192711Patent 6870037Patent 6482934Patent 6387619Patent 6043216Patent 5916752Patent 5786344Patent 5698686Patent 5618917

Abstract

The Transgenic Mouse and Embryonic Stem Cell Facility is a shared facility designed to generate transgenic and knockout mice for researchers at the University of Chicago. Most of these experiments are being conducted by members of the University of Chicago Cancer Research Center, and many of these experiments have direct implications not only for our understanding of cancer, but also for generating animal model systems that will be important for developing new and improved diagnostic and therapeutic tools for cancer. Five services are currently provided by the Facility: (1) preparation of transgenic mice, through the F1 generation; (2) embryo freezing; (3) clean mouse strain rederivation from either frozen embryos or embryos obtained from non-pathogen free mice; (4) transfer of embryonic stem cells to mouse blastocysts, and subsequent generation of chimeric, heterozygous and homozygous mice targeted for a particular null mutation and (5) timed mouse pregnancies. Projects carried out by the facility have been funded by a peer-reviewed federal or private grant, and the experimental protocol receives prior approval from the University Animal Care Committee. Projects include: (l) targeting growth factors and cytokines to stratified squamous epithelia, and examining the relation of these alterations to hyperproliferative disorders of the epidermis; (2) altering the expression of cell survival factors in mice and examining the molecular consequences; (3) perturbing growth control and inflammatory responses in cells of the immune system; (4) examining the roles of chromosomal breakpoint genes on tumorigenesis; (5) examining the functions of transcription factors on cell-type specific gene expression, development and differentiation, and assessing the biological consequences and relevance to cancer when they are misregulated; (6) exploring mechanisms of somatic hypermutation of genes in B-cell development; (7) understanding the mechanisms underlying processing and presentation of major histocompatibility antigens, and how these processes can go awry in genetic disorders. These studies have been central to the investigative goals of cancer researchers on campus; the contributions are of fundamental importance to our understanding of cancer.

View original record on NIH RePORTER →